Planning target volume as predictor of disease progression ...

lung cancer is a very heterogeneous disease in terms of macroscopic tumor extent and patient prognosis. Histori-cally only ten to thirty percent of these patients survive ve years after multimodal treatment [2 –4]. Regarding inoperable stage III NSCLC, the implementa-tion of CPI as one of the key components of a multimodal ................
................